NCT01362036View on ClinicalTrials.gov

Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG

TXA127

Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection

Trial Locations (1)

77230-1402

MD Anderson Leukemia Department, Houston

Sponsors
All Listed Sponsors
lead

Tarix Pharmaceuticals

INDUSTRY